Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0019)
Name
Testosterone
Synonyms
testosterone; 58-22-0; Androderm; Testim; Testosteron; Mertestate; Testoderm; Virosterone; Sustanon; Homosterone; Androlin; Testiculosterone; AndroGel; Synandrol F; Testosteroid; Andronaq; Andropatch; Andrusol; Homosteron; Orquisteron; Perandren; Primotest; Primoteston; Sustanone; Testandrone; Testobase; Testogel; Testopropon; Testrone; Oreton; Relibra; Teslen; Testryl; Cristerona T; Testoviron T; Neotestis; Malerone; trans-Testosterone; Cristerone T; Testoviron Schering; Geno-cristaux gremy; Testostosterone; Testolin; Testoviron; LibiGel; 17beta-Hydroxyandrost-4-en-3-one; Sustason 250; Percutacrine androgenique; Neo-Hombreol F; Oreton-F; Testosteronum; Intrinsa; Testosterona; Striant; Testoject-50; Testoderm Tts; Testosterone hydrate; Neo-testis; Testro AQ; Malestrone (amps); Andro 100; Virormone; beta testosterone; Malogen, aquaspension injection; Vogelxo; Testosteronum [INN-Latin]; Testosterona [INN-Spanish]; Androst-4-en-17beta-ol-3-one; CDB 111C; Livensa; Nasobol; Natesto; Axiron; Tefina; CompleoTRT; Testopel Pellets; 17beta-Hydroxy-4-androsten-3-one; 7-beta-Hydroxyandrost-4-en-3-one; COL 1621; delta4-Androsten-17beta-ol-3-one; Testosterone ciii; 17beta-Hydroxyandrost-4-ene-3-one; 17-beta-Hydroxyandrost-4-en-3-one; 4-Androsten-17beta-ol-3-one; Androgel 1%; CP 601B; CCRIS 574; 17-Hydroxy-(17beta)-androst-4-en-3-one; Androgel 1.62%; 17beta-Hydroxy-delta(sup4)-androsten-3-one; delta(sup 4)-Androsten-17(beta)-ol-3-one; 17-Hydroxy-(17-beta)-androst-4-en-3-one; 17-beta-Hydroxy-delta(sup 4)-androsten-3-one; AA 2500; Androst-4-en-3-one, 17beta-hydroxy-; CHEBI:17347; HSDB 3398; Androst-4-en-3-one, 17-beta-hydroxy-; NSC 9700; EINECS 200-370-5; (+)-testosterone; UNII-3XMK78S47O; ANDROLAN; Androst-4-en-3-one, 17-hydroxy-, (17beta)-; 3XMK78S47O; DTXSID8022371; (17beta)-17-Hydroxyandrost-4-en-3-one; Oreton F; ANDROID-T; LPCN 1021; NSC-9700; Androst-4-en-3-one, 17-hydroxy-, (17-beta)-; DTXCID302371; (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; Androst-4-en-3-one, 17-hydroxy-, (17b)-; EC 200-370-5; TESTOSTERONE (MART.); TESTOSTERONE [MART.]; Halotensin; Androsorb; Fortesta; Testaqua; Testopel; TESTOSTERONE (EP IMPURITY); TESTOSTERONE [EP IMPURITY]; TESTOSTERONE (EP MONOGRAPH); TESTOSTERONE [EP MONOGRAPH]; Androst-4-en-3-one, 17-hydroxy-, (17.beta.)-; TESTOSTERONE (USP MONOGRAPH); TESTOSTERONE [USP MONOGRAPH]; T-Cypionate; (8alpha,10alpha,13alpha,14beta,17alpha)-17-hydroxyandrost-4-en-3-one; Virilon IM; Testrin-P.A; Androderm (TN); 17.beta.-Testosterone; Androgel (TN); SMR000058344; Andronate 100; Andronate 200; Andropository 200; Striant (TN); Testamone 100; Bio-T-Gel; Testim (TN); Everone 200; Andryl 200; Scheinpharm Testone-Cyp; Testred Cypionate 200; Testosterone (JAN/USP); Androst-4-en-3-on-17B-ol; CHEMBL386630; component of Duogen (Salt/Mix); component of Tostrex (Salt/Mix); component of Di-Met (Salt/Mix); NSC9700; component of Intrinsa (Salt/Mix); Epitestosteron; Lumitestosteron; 4-Androsten-17.beta.-ol-3-one; 4-Androsten-3-one-17.beta.-ol; Tostrelle; Tostrex; Viatrel; component of Di-Genik (Salt/Mix); 4-Androsten-3-one, 17b-hydroxy-; Testosterone [USP:INN:BAN]; 9b-testosterone; component of Mal-O-Fem (Salt/Mix); Testostroval-PA; 4-androstene-17beta-ol-3-one; 17b-hydroxy-4-androsten-3-one; delta4-androsten-17b-ol-3-one; Testosterone, 1; 3kdm; 17b-Testosterone; 17-.beta.-Hydroxyandrost-4-en-3-one; NCGC00091018-01; 8-iso-testosterone; 17 beta Hydroxy 4 Androsten 3 one; 17-beta-Hydroxy-4-Androsten-3-one; (+-)-testosterone; Axiron (TN); CMC_13449; 13-iso-testosterone; mpp10; TESTSTERONE; 9b,10a-testosterone; 17.beta.-Hydroxy-.DELTA.4-androsten-3-one; 17-Hydroxyandrost-4-en-3-one, (17.beta.)-; Therapeutic Testosterone; (+-)-retrotestosterone; Testosterone, >=98%; TESTOSTERONE [MI]; TESTOSTERONE [INN]; TESTOSTERONE [JAN]; Epitope ID:135865; TESTOSTERONE [HSDB]; TESTOSTERONE [INCI]; Testosterone EP Impurity C; (+-)-8-iso-testosterone; SCHEMBL8452; TESTOSTERONE [VANDF]; 4-Androsten-3-one-17b-ol; MLS000563091; MLS001032098; MLS001306401; MLS001424262; MLS002174283; BIDD:ER0555; TESTOSTERONE [WHO-DD]; D4-Androsten-17b-ol-3-one; Androst-4-en-17b-ol-3-one; BDBM8885; GTPL2858; Androst-4-ene-17b-ol-3-one; TESTOSTERONE [EMA EPAR]; 17-hydroxy-D4-androsten-3-one; 17-hydroxy-androst-4-en-3-one; 17beta-hydroxy-4-androsten-3one; TESTOSTERONE [GREEN BOOK]; Testosterone, cell culture tested; 17b-Hydroxy-androst-4-en-3-on; 17b-Hydroxy-D4-androsten-3-one; 17b-Hydroxyandrost-4-ene-3-one; 1i37; Testosterone, 1mg/ml in Methanol; 17a-hydroxy-androst-4-en-3-one; 17b-hydroxy-androst-4-en-3-one; HMS2052N11; HMS2272B03; HMS2272P03; TESTOSTERONE [ORANGE BOOK]; (8R,9S,10R,13S,14S,17S)-17-Hydroxy-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one; 17-Hydroxy-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one; Tox21_200689; HY-15554A; LMST02020002; RB3046; 17b-hydroxy-8a-androst-4-en-3-one; rac-17b-hydroxy-androst-4-en-3-one; AKOS015894897; 17a-hydroxy-13a-androst-4-en-3-one; 17a-hydroxy-14b-androst-4-en-3-one; 17b-hydroxy-13a-androst-4-en-3-one; CCG-101189; CS-1415; DB00624; Human Serum - Testosterone, low level; NC00439; CAS-58-22-0; Human Serum - Testosterone, high level; Testosterone 1.0 mg/ml in Acetonitrile; (17?)-17-Hydroxyandrost-4-en-3-one; 17b-hydroxy-(8a)-androst-4-en-3-one; 17b-hydroxy-(9b)-androst-4-en-3-one; NCGC00258243-01; (17b)-17-hydroxy-androst-4-en-3-one; 17a-hydroxy-(13a)-androst-4-en-3-one; 17b-hydroxy-(10a)-androst-4-en-3-one; 17b-hydroxy-(13a)-androst-4-en-3-one; AC-14899; CPD000058344; SMR001261453; Testosterone, purum, >=99.0% (HPLC); Testosterone 100 microg/mL in Acetonitrile; rac-17b-hydroxy-(13a)androst-4-en-3-one; rac-17b-hydroxy-(8a)-androst-4-en-3-one; T0027; 17b-hydroxy-(8a,10a)-androst-4-en-3-one; 17b-hydroxy-(9b,10a)-androst-4-en-3-one; BIM-0061761.0001; C00535; D00075; rac-17b-hydroxy-(9b,10a)androst-4-en-3-one; S00309; AB00973630-03; Testosterone, VETRANAL(TM), analytical standard; Androst-4-en-3-one, 17-hydroxy, (17.beta.)-; Q-101251; Q1318776; B5DEE83F-632B-48A1-A0ED-A51E7F13DF2E; TESTOSTERONE ENANTATE IMPURITY D [EP IMPURITY]; TESTOSTERONE PROPIONATE IMPURITY C [EP IMPURITY]; Testosterone, European Pharmacopoeia (EP) Reference Standard; Testosterone; 4-Androsten-17?-ol-3-one; 17?-Hydroxy-4-androsten-3-one; Testosterone for impurity D identification, European Pharmacopoeia (EP) Reference Standard; Testosterone for system suitability, European Pharmacopoeia (EP) Reference Standard; (1S,2R,10R,11S,14S,15S)-14-hydroxy-2,15-dimethyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadec-6-en-5-one; 1050678-68-6; 17?-hydroxyandrost-4-en-3-one; epitestosterone; 17-epi-Testosterone; 17?-cis-Testosterone; 4-Androstene-17?-ol-3-one; Isotestosterone

    Click to Show/Hide
Status
Approved
Drug Type
Small molecular drug
Structure
Formula
C19H28O2
IUPAC Name
(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
Canonical SMILES
CC12CCC3C(C1CCC2O)CCC4=CC(=O)CCC34C
InChI
InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1
InChIKey
MUMGGOZAMZWBJJ-DYKIIFRCSA-N
PubChem CID
6013
TTD Drug ID
D06XMU
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Prostate cancer ICD-11: 2C82
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell autophagy
In Vitro Model LNCaP cells Prostate carcinoma Homo sapiens CVCL_0395
LAPC-4 cells Prostate carcinoma Homo sapiens CVCL_4744
HEK-293T cells Normal Homo sapiens CVCL_0063
NK-92 cells Natural killer cell lymphoblastic leukemia Homo sapiens CVCL_2142
22Rv1 cells Prostate carcinoma Homo sapiens CVCL_1045
In Vivo Model
Adult athymic nude mice were inoculated subcutaneously in the flank with the LNCaP human prostate cancer cell lines in 200 uL of Matrigel. Mice were divided into two groups, and the treatment group was implanted with 2 one cm long silastic implants filled with testosterone as described previously. Tumors were harvested 2- and 4-days post-treatment and fixed in 10% buffered formalin and processed for IHC and H&E staining.

    Click to Show/Hide
Response regulation Testosterone induces two parallel autophagy-mediated processes, ferritinophagy and nucleophagy, which then activate nucleic acid sensors to drive immune signaling pathways in prostate cancer.
References
Ref 1 Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer. Cancer Res. 2021 Dec 1;81(23):5948-5962. doi: 10.1158/0008-5472.CAN-20-3607. Epub 2021 Oct 13.